FDA to make a decision on whether to approve first Alzheimer’s drug

Indonesia Berita Berita

FDA to make a decision on whether to approve first Alzheimer’s drug
Indonesia Berita Terbaru,Indonesia Berita utama
  • 📰 wjxt4
  • ⏱ Reading Time:
  • 36 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 63%

The FDA is set to decide whether it will fully approve the first Alzheimer’s drug,

FILE - This Dec. 21, 2022, image provided by Eisai in January 2023 shows vials and packaging for their medication Leqembi. On Friday, June 9, 2023, health advisers backed the full approval of the closely watched Alzheimers drug, a key step toward opening insurance coverage to U.S. seniors with early stages of the brain-robbing disease.

But the decision could also have other implications, including who would get access to it. Six years ago, Joe Montminy saw a neurologist for what he thought were a few minor problems with his memory. Now 59-years-old, Montminy is one of millions of Americans living with Alzheimer’s disease. But this year, new hope has emerged. A drug aiming to slow down the disease’s progression got accelerated FDA approval in January based on the fact that it clears amyloid plaque buildups in the brain associated with Alzheimer’s.

“You had this treatment at your fingertips and suddenly you had Medicare saying, yeah, but you can’t quite get access to that at this point in time,” Montminy said.

Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

wjxt4 /  🏆 246. in US

Indonesia Berita Terbaru, Indonesia Berita utama

Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.

FDA Approves First Leadless Dual-Chamber Pacing SystemFDA Approves First Leadless Dual-Chamber Pacing SystemThe FDA has approved 'the world's first' leadless dual-chamber pacing system, one based in part on an already-approved leadless single-chamber device. MedicalNews CardioTwitter
Baca lebih lajut »

FDA Gives The Okay For Abbott’s New Minimally Invasive PacemakerFDA Gives The Okay For Abbott’s New Minimally Invasive PacemakerOn Wednesday, medtech giant Abbott announced that its new leadless pacemaker system, Aveir DR, has been approved by the FDA. This is the first time the FDA has given a thumbs up to a device of this type for two different chambers of the heart.
Baca lebih lajut »

FDA, FTC warn 6 companies allegedly selling delta-8 THC infused foods with confusing labelingFDA, FTC warn 6 companies allegedly selling delta-8 THC infused foods with confusing labelingThe FDA and Federal Trade Commission have issued warning letters to six companies it says are illegally selling copycat foods infused with delta-8 THC.
Baca lebih lajut »

InnovationRx: FDA OKs Abbott’s New PacemakerInnovationRx: FDA OKs Abbott’s New PacemakerInnovationRx is your weekly digest of healthcare news. Sign up!
Baca lebih lajut »

House Oversight calls for interviews with eight top FDA officials over baby formula shortageHouse Oversight calls for interviews with eight top FDA officials over baby formula shortageThe House Oversight Subcommittee on Health Care and Financial Services is calling for transcribed interviews from eight top Food and Drug Administration officials relating to the infant formula shortage.
Baca lebih lajut »

FDA Gives The Okay For Abbott’s New Minimally Invasive PacemakerFDA Gives The Okay For Abbott’s New Minimally Invasive PacemakerMedtech giant Abbott announced that its new leadless pacemaker system, Aveir DR, has been approved by the FDA.
Baca lebih lajut »



Render Time: 2025-03-03 00:24:40